DEA Stretches Virtual Controlled Drug Prescriptions to 2026
Published Date: 12/31/2025
Rule
Summary
The DEA and HHS are extending special telemedicine rules that let doctors prescribe controlled medications without an in-person visit through December 31, 2026. This helps patients who need these meds get care safely from home. Doctors and patients can keep using telehealth for these prescriptions without extra costs or delays during this time.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Keep Telemedicine Prescriptions Open
You can continue to get prescriptions for Schedule II-V controlled medications by telemedicine without an in-person medical visit if the rule's conditions are met. The temporary extension covers telemedicine prescribing from May 12, 2023 through December 31, 2026 and the rule is effective January 1, 2026 through December 31, 2026. The agencies note that in 2024 about 7 million prescriptions (roughly 16 percent of 44.6 million) were issued without a prior in-person medical evaluation.
Estimated Patient Cost Savings
DEA and HHS estimate patient cost savings from this extension: $18.4 million in the first year and a net present value of $17.2 million at a 7% discount rate. The agencies say the extension creates cost savings to patients and prescribers by avoiding the need for some in-person care during the extension period through December 31, 2026.
Fewer Requirements Than Final Rules
The temporary rule imposes fewer requirements than two related final rules that also address telemedicine prescribing. Practitioners who are covered by one or both of the Two Final Rules may still use this temporary extension (through December 31, 2026) so long as they meet the temporary rule's conditions, which can reduce compliance burdens during the extension.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2025-05007 — Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans and others needing buprenorphine treatment can get care through telemedicine, making it easier and faster to access help. The government delayed these new rules to review feedback and make sure everything’s just right. This change means more people can get treatment from home without extra costs or trips to the doctor.
2025-02793 — Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting March 21, 2025, veterans and others needing buprenorphine treatment can get care through telemedicine more easily. The government is delaying new rules to make sure everything’s just right and wants your thoughts on the delay. This change helps veterans keep their treatment going without extra trips, saving time and hassle.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
Previous / Next Documents
Previous: 2025-24113 — Cotton Board Rules and Regulations: Adjusting Supplemental Assessment on Imports (2025 Amendments)
Starting March 1, 2026, importers of cotton and cotton products will see a change in how their supplemental fees are calculated. The USDA is lowering the value assigned to imported cotton to match the fees paid on U.S.-grown cotton, keeping things fair. This update also refreshes the Import Assessment Table to reflect recent changes since 2024.
Next: 2025-24127 — Delegation of Authority to the Director of the Division of Investment Management
Starting December 31, 2025, the Director of the Division of Investment Management gets the power to approve or deny requests to keep certain investment info secret. This change helps the SEC work faster and saves resources by letting the Director handle these decisions directly. It mainly affects companies filing investment adviser info and speeds up how confidential info is managed.